<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: Dapagliflozin, a novel inhibitor of renal <z:chebi fb="199" ids="26708">sodium</z:chebi>-<z:chebi fb="105" ids="17234">glucose</z:chebi> cotransporter 2, allows an insulin-independent approach to improve type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>In this multiple-dose study we evaluated the safety and efficacy of dapagliflozin in type 2 diabetic patients </plain></SENT>
<SENT sid="2" pm="."><plain>RESEARCH DESIGN AND METHODS: Type 2 diabetic patients were randomly assigned to one of five dapagliflozin doses, <z:chebi fb="0" ids="6801">metformin</z:chebi> XR, or placebo for 12 weeks </plain></SENT>
<SENT sid="3" pm="."><plain>The primary objective was to compare mean change from baseline in A1C </plain></SENT>
<SENT sid="4" pm="."><plain>Other objectives included comparison of changes in fasting plasma <z:chebi fb="105" ids="17234">glucose</z:chebi> (FPG), weight, adverse events, and laboratory measurements </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: After 12 weeks, dapagliflozin induced moderate <z:hpo ids='HP_0003076'>glucosuria</z:hpo> (52-85 g urinary <z:chebi fb="105" ids="17234">glucose</z:chebi>/day) and demonstrated significant glycemic improvements versus placebo (DeltaA1C -0.55 to -0.90% and DeltaFPG -16 to -31 mg/dl) </plain></SENT>
<SENT sid="6" pm="."><plain><z:hpo ids='HP_0001824'>Weight loss</z:hpo> change versus placebo was -1.3 to -2.0 kg </plain></SENT>
<SENT sid="7" pm="."><plain>There was no change in renal function </plain></SENT>
<SENT sid="8" pm="."><plain>Serum <z:chebi fb="3" ids="27226">uric acid</z:chebi> decreased, serum <z:chebi fb="131" ids="25107">magnesium</z:chebi> increased, serum phosphate increased at higher doses, and dose-related 24-h urine volume and hematocrit increased, <z:hpo ids='HP_0000001'>all</z:hpo> of small magnitude </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment-emergent adverse events were similar across <z:hpo ids='HP_0000001'>all</z:hpo> groups </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSIONS: Dapagliflozin improved <z:hpo ids='HP_0003074'>hyperglycemia</z:hpo> and facilitates <z:hpo ids='HP_0001824'>weight loss</z:hpo> in type 2 diabetic patients by inducing controlled <z:hpo ids='HP_0003076'>glucosuria</z:hpo> with urinary loss of approximately 200-300 kcal/day </plain></SENT>
<SENT sid="11" pm="."><plain>Dapagliflozin treatment demonstrated no persistent, clinically significant osmolarity, volume, or renal status changes </plain></SENT>
</text></document>